Tandem Diabetes Care (TNDM) Financials

$21.32 +0.03 (+0.14%)

Closing price 05/6/2025 04:00 PM Eastern

Extended Trading

$20.94 -0.38 (-1.76%)

As of 05/6/2025 05:28 PM Eastern

Annual Income Statements for Tandem Diabetes Care

This table shows Tandem Diabetes Care's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-80	-72	-83	-73	-123	-25	-34	15	-96	-219	-99
Consolidated Net Income / (Loss)	-80	-72	-83	-73	-123	-25	-34	16	-95	-223	-96
Net Income / (Loss) Continuing Operations	-80	-72	-83	-73	-123	-25	-34	16	-95	-223	-96
Total Pre-Tax Income	-79	-72	-83	-73	-123	-25	-36	16	-93	-220	-92
Total Operating Income	-76	-69	-78	-63	-45	-17	-7.96	23	-93	-233	-99
Total Gross Profit	15	27	24	44	90	194	261	376	413	368	490
Total Revenue	50	73	84	108	184	362	499	703	801	748	940
Operating Revenue	50	73	84	108	184	362	499	703	801	748	940
Total Cost of Revenue	34	46	61	64	94	168	238	327	388	380	451
Operating Cost of Revenue	34	46	61	64	94	168	238	327	388	380	451
Total Operating Expenses	91	96	102	107	134	211	268	354	506	601	589
Selling, General & Admin Expense	75	79	83	86	105	166	205	262	336	353	390
Research & Development Expense	16	17	19	21	29	45	64	92	170	248	199
Total Other Income / (Expense), net	-3.79	-3.40	-5.41	-10	-78	-7.88	-28	-6.75	-0.00	13	7.26
Interest Expense	3.90	3.74	5.71	11	13	0.00	13	6.04	6.21	9.88	8.68
Interest & Investment Income	0.11	0.34	0.30	0.24	1.44	3.19	1.57	0.67	6.06	23	16
Other Income / (Expense), net	-	-	-	1.02	-66	-11	-17	-1.39	0.15	0.00	0.00
Income Tax Expense	0.07	0.01	-0.02	0.01	0.05	0.15	-1.90	0.34	1.74	2.36	4.16
Basic Earnings per Share	($3.42)	($25.04)	($27.30)	($12.87)	($2.55)	($0.42)	($0.56)	$0.25	($1.47)	($3.43)	($1.47)
Weighted Average Basic Shares Outstanding	23.27M	2.89M	3.06M	5.68M	48.13M	58.51M	60.99M	63M	64.15M	64.97M	65.45M
Diluted Earnings per Share	($3.42)	($25.04)	($27.30)	($12.87)	($2.55)	($0.42)	($0.56)	$0.24	($1.47)	($3.43)	($1.47)
Weighted Average Diluted Shares Outstanding	23.27M	2.89M	3.06M	5.68M	48.13M	58.51M	60.99M	64.35M	64.15M	64.97M	65.45M
Weighted Average Basic & Diluted Shares Outstanding	23.27M	2.89M	3.06M	5.68M	48.13M	58.51M	60.99M	63.87M	64.53M	65.63M	66.47M

This table shows Tandem Diabetes Care's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-50	-15	-122	-37	-34	-26	-45	-31	-23	0.06	-129
Consolidated Net Income / (Loss)	-49	-16	-124	-36	-33	-30	-43	-31	-23	0.76	-131
Net Income / (Loss) Continuing Operations	-49	-16	-124	-36	-33	-30	-43	-31	-23	0.76	-131
Total Pre-Tax Income	-47	-16	-124	-35	-31	-31	-40	-30	-23	0.02	-122
Total Operating Income	-47	-18	-128	-39	-32	-35	-42	-31	-26	-0.58	-121
Total Gross Profit	104	116	83	102	90	93	95	113	125	157	118
Total Revenue	205	221	169	196	186	197	192	222	244	283	234
Operating Revenue	205	221	169	196	186	197	192	222	244	283	234
Total Cost of Revenue	100	105	86	94	96	104	97	109	119	125	116
Operating Cost of Revenue	100	105	86	94	96	104	97	109	119	125	116
Total Operating Expenses	152	133	211	141	121	128	136	144	151	158	239
Selling, General & Admin Expense	84	98	90	98	79	86	90	94	100	106	114
Research & Development Expense	68	36	121	43	42	43	46	49	51	52	125
Total Other Income / (Expense), net	0.14	1.66	4.23	4.18	0.82	3.75	2.15	1.03	3.48	0.60	-1.21
Interest Expense	1.58	1.58	1.63	1.61	4.84	1.80	3.17	1.79	1.87	1.86	1.86
Interest & Investment Income	1.72	3.10	5.87	5.78	5.66	5.55	5.31	2.82	5.34	2.46	0.65
Income Tax Expense	1.62	-0.26	0.29	1.15	2.23	-1.31	3.19	1.07	0.64	-0.74	8.47
Basic Earnings per Share	($0.76)	($0.25)	($1.92)	($0.55)	($0.51)	($0.45)	($0.65)	($0.47)	($0.35)	-	($1.97)
Weighted Average Basic Shares Outstanding	64.24M	64.15M	64.55M	64.83M	65.12M	64.97M	65.33M	64.99M	65.54M	65.45M	66.40M
Diluted Earnings per Share	($0.76)	($0.24)	($1.92)	($0.55)	($0.51)	($0.45)	($0.65)	($0.47)	($0.35)	-	($1.97)
Weighted Average Diluted Shares Outstanding	64.24M	64.15M	64.55M	64.83M	65.12M	64.97M	65.33M	64.99M	65.54M	65.45M	66.40M
Weighted Average Basic & Diluted Shares Outstanding	64.30M	64.53M	64.62M	65.08M	65.21M	65.63M	64.59M	65.46M	65.68M	66.47M	66.61M

This table details how cash moves in and out of Tandem Diabetes Care's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-93	12	1.59	-23	18	9.35	43	-23	101	-114	10
Net Cash From Operating Activities	-61	-59	-61	-66	-8.32	42	25	111	50	-32	24
Net Cash From Continuing Operating Activities	-61	-59	-61	-66	-8.32	42	25	111	50	-32	24
Net Income / (Loss) Continuing Operations	-80	-72	-83	-73	-123	-25	-34	16	-95	-223	-96
Consolidated Net Income / (Loss)	-80	-72	-83	-73	-123	-25	-34	16	-95	-223	-96
Depreciation Expense	4.39	4.83	5.49	6.87	5.82	6.07	10	14	14	16	17
Amortization Expense	0.17	0.14	0.19	1.87	2.26	-0.57	8.80	2.09	6.08	5.79	-0.23
Non-Cash Adjustments To Reconcile Net Income	15	14	17	14	98	78	79	63	128	186	117
Changes in Operating Assets and Liabilities, net	-1.76	-5.04	0.03	-16	8.61	-17	-39	17	-3.66	-17	-13
Net Cash From Investing Activities	-35	2.42	10	2.78	-91	-57	-296	-187	33	-86	-23
Net Cash From Continuing Investing Activities	-35	2.42	10	2.78	-91	-57	-296	-187	33	-86	-23
Purchase of Property, Plant & Equipment	-4.41	-5.76	-8.93	-5.72	-2.99	-20	-27	-14	-34	-27	-19
Acquisitions	-0.17	-0.07	-	-	0.00	-	0.00	0.00	-26	-69	0.00
Purchase of Investments	-67	-80	-31	0.00	-124	-165	-502	-733	-468	-511	-264
Sale and/or Maturity of Investments	36	88	50	8.50	36	127	233	570	569	546	306
Other Investing Activities, net	-	-	-	-	-	-	-	-9.33	-8.86	-25	-46
Net Cash From Financing Activities	3.64	68	52	40	117	24	314	52	17	4.11	8.37
Net Cash From Continuing Financing Activities	3.64	68	52	40	117	24	314	52	17	4.11	8.37
Repayment of Debt	-30	-	-	0.00	-88	-	0.00	0.00	-0.59	-0.07	-246
Repurchase of Common Equity	-	-	-	-	-	-	-	-	0.00	0.00	-30
Issuance of Debt	30	-	50	-	0.00	0.00	279	-	0.00	0.00	307
Issuance of Common Equity	3.66	3.39	2.32	40	2.39	24	67	51	17	4.18	-6.73
Other Financing Activities, net	0.05	65	-	0.00	203	0.33	-31	0.59	0.00	0.00	-16
Effect of Exchange Rate Changes	-	-	-	-	-	0.19	0.39	0.15	0.83	-0.21	1.26
Cash Interest Paid	3.37	3.35	4.40	7.88	11	0.00	2.71	4.31	4.31	7.57	3.08
Cash Income Taxes Paid	0.07	0.01	0.02	0.02	0.02	0.07	0.18	0.26	0.41	1.92	3.10

This table details how cash moves in and out of Tandem Diabetes Care's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Change in Cash & Equivalents	8.82	49	-45	2.99	-51	-21	0.11	-11	1.34	20	-16
Net Cash From Operating Activities	24	5.82	-18	-6.32	0.06	-7.22	-8.00	-5.28	27	11	-18
Net Cash From Continuing Operating Activities	24	5.82	-18	-6.32	0.06	-7.22	-8.00	-5.28	27	11	-18
Net Income / (Loss) Continuing Operations	-49	-16	-124	-36	-33	-30	-43	-31	-23	0.76	-131
Consolidated Net Income / (Loss)	-49	-16	-124	-36	-33	-30	-43	-31	-23	0.76	-131
Depreciation Expense	3.51	3.64	3.40	4.27	4.02	4.03	4.04	4.11	4.21	4.25	4.31
Amortization Expense	2.08	1.31	0.82	1.95	2.12	0.90	0.22	1.22	-0.44	-1.22	-0.64
Non-Cash Adjustments To Reconcile Net Income	54	33	101	39	22	24	26	28	30	33	112
Changes in Operating Assets and Liabilities, net	13	-16	0.01	-16	4.82	-6.36	4.96	-8.21	16	-26	-3.77
Net Cash From Investing Activities	-14	36	-26	5.70	-49	-17	-5.06	-3.54	-20	5.01	9.19
Net Cash From Continuing Investing Activities	-14	36	-26	5.70	-49	-17	-5.06	-3.54	-20	5.01	9.19
Purchase of Property, Plant & Equipment	-14	-5.63	-8.83	-7.38	-5.40	-5.20	-4.46	-6.47	-5.24	-3.07	-2.97
Acquisitions	-26	-0.02	-69	-	-	-	0.00	-	-	-	-43
Purchase of Investments	-132	-105	-109	-126	-156	-120	-84	-93	-74	-13	-9.45
Sale and/or Maturity of Investments	166	147	163	140	112	131	84	96	59	67	65
Net Cash From Financing Activities	-0.77	6.10	-0.54	3.95	-1.91	2.62	14	-3.00	-4.52	2.30	-4.69
Net Cash From Continuing Financing Activities	-0.77	6.10	-0.54	3.95	-1.91	2.62	14	-3.00	-4.52	2.30	-4.69
Repayment of Debt	-0.41	0.08	0.00	-	-0.07	-	-246	-	-	-	0.00
Repurchase of Common Equity	-	-	0.00	-	-	-	-30	-	-	-	0.00
Issuance of Debt	-	-	0.00	-	-	-	307	-	-	-	0.00
Other Financing Activities, net	-	-0.08	0.00	-	-	-	-16	-	-	-	-4.69
Effect of Exchange Rate Changes	-0.19	1.03	0.44	-0.33	-0.76	0.44	-0.42	0.54	-1.02	2.17	-1.88
Cash Income Taxes Paid	-	0.25	0.37	1.40	-	0.15	0.27	0.91	0.12	1.80	1.56

This table presents Tandem Diabetes Care's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	106	125	112	95	206	326	716	905	1,053	953	968
Total Current Assets	91	107	92	64	188	276	637	812	850	748	724
Cash & Equivalents	31	43	45	14	42	51	95	71	173	59	69
Short-Term Investments	36	28	8.86	0.48	87	125	390	553	444	409	369
Accounts Receivable	7.65	14	11	21	35	47	82	111	115	106	115
Inventories, net	12	18	21	27	20	49	64	69	111	158	150
Prepaid Expenses	1.90	2.28	4.19	2.19	3.77	4.03	6.38	8.43	7.24	17	22
Plant, Property, & Equipment, net	13	16	18	20	17	33	50	50	69	77	78
Total Noncurrent Assets	3.13	2.22	1.89	12	1.26	17	29	43	134	128	165
Long-Term Investments	-	-	-	-	-	-	-	-	-	0.00	75
Other Noncurrent Operating Assets	0.69	0.11	0.11	0.10	1.26	17	29	43	134	128	90
Total Liabilities & Shareholders' Equity	106	125	112	95	206	326	716	905	1,053	953	968
Total Liabilities	52	61	118	124	75	131	350	472	613	639	705
Total Current Liabilities	18	27	31	36	66	99	104	132	165	195	247
Short-Term Debt	-	-	-	-	-	-	-	-	-	0.00	41
Accounts Payable	1.95	5.23	7.51	5.15	6.82	18	18	28	56	50	45
Accrued Expenses	2.92	2.12	1.63	2.83	3.93	8.01	4.78	9.42	9.60	13	18
Current Deferred Revenue	0.84	1.82	5.21	2.53	4.60	3.87	6.08	10	19	44	12
Current Employee Benefit Liabilities	9.72	12	10	14	24	28	34	52	39	43	64
Other Current Liabilities	2.66	5.58	6.94	11	27	41	41	33	42	46	68
Total Noncurrent Liabilities	34	35	87	88	8.73	32	246	340	448	444	458
Long-Term Debt	29	29	79	77	-	0.00	203	281	283	285	308
Noncurrent Deferred Revenue	2.70	2.74	2.61	4.69	-	-	-	17	17	13	10
Other Noncurrent Operating Liabilities	1.66	2.72	5.27	7.18	8.73	32	43	42	147	145	139
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	55	63	-5.93	-29	131	195	366	433	440	314	263
Total Preferred & Common Equity	55	63	-5.93	-29	131	195	366	433	440	314	263
Total Common Equity	55	63	-5.93	-29	131	195	366	433	440	314	263
Common Stock	303	385	399	448	731	820	1,025	1,068	1,171	1,264	1,313
Retained Earnings	-249	-321	-405	-478	-600	-625	-659	-635	-729	-952	-1,048
Accumulated Other Comprehensive Income / (Loss)	0.01	0.02	-0.00	-	-0.01	0.12	0.22	-0.62	-1.82	1.37	-1.95

This table presents Tandem Diabetes Care's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025
Total Assets	1,048	954	947	940	941	938	958	922
Total Current Assets	834	758	764	758	735	733	753	663
Cash & Equivalents	124	128	131	80	59	48	49	54
Short-Term Investments	485	392	376	419	409	405	424	315
Accounts Receivable	113	91	99	100	93	98	107	127
Inventories, net	105	132	148	143	154	162	152	141
Prepaid Expenses	8.00	15	11	16	21	21	20	27
Plant, Property, & Equipment, net	73	75	74	76	78	79	81	79
Total Noncurrent Assets	140	122	109	106	128	125	124	179
Long-Term Investments	-	-	-	-	-	-	-	71
Other Noncurrent Operating Assets	140	122	109	106	128	125	124	108
Total Liabilities & Shareholders' Equity	1,048	954	947	940	941	938	958	922
Total Liabilities	626	615	617	626	698	704	720	767
Total Current Liabilities	174	171	175	187	193	241	259	288
Short-Term Debt	-	-	-	-	-	41	41	41
Accounts Payable	62	55	57	46	48	48	49	60
Accrued Expenses	7.90	10	13	14	11	13	12	14
Current Deferred Revenue	13	21	23	32	45	44	43	11
Current Employee Benefit Liabilities	48	39	35	44	42	43	59	50
Other Current Liabilities	43	46	46	52	48	52	56	113
Total Noncurrent Liabilities	452	444	443	439	505	463	461	479
Long-Term Debt	283	284	284	285	347	307	308	309
Noncurrent Deferred Revenue	19	16	15	14	12	12	11	9.86
Other Noncurrent Operating Liabilities	150	145	143	140	145	144	142	160
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	422	339	329	314	243	234	238	155
Total Preferred & Common Equity	422	339	329	314	243	234	238	155
Total Common Equity	422	339	329	314	243	234	238	155
Common Stock	1,140	1,192	1,219	1,238	1,239	1,260	1,282	1,334
Retained Earnings	-713	-853	-889	-922	-995	-1,025	-1,049	-1,178
Accumulated Other Comprehensive Income / (Loss)	-5.06	-0.09	-1.19	-2.21	-0.94	-1.25	3.87	0.08

This table displays calculated financial ratios and metrics derived from Tandem Diabetes Care's official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	71.41%	46.51%	15.65%	27.72%	70.88%	97.05%	37.68%	40.89%	14.00%	-6.68%	25.74%
EBITDA Growth	-30.06%	9.95%	-13.02%	26.51%	-93.73%	78.37%	74.01%	742.22%	-294.30%	-192.89%	60.92%
EBIT Growth	-29.48%	8.80%	-13.11%	20.66%	-79.46%	74.99%	9.90%	184.92%	-535.89%	-151.59%	57.50%
NOPAT Growth	-53.06%	8.80%	-13.11%	19.36%	29.09%	62.53%	52.42%	498.14%	-393.08%	-151.20%	57.50%
Net Income Growth	-25.95%	8.94%	-15.23%	12.48%	-67.88%	79.81%	-38.90%	145.27%	-707.70%	-135.33%	56.86%
EPS Growth	84.06%	8.94%	-15.23%	52.86%	80.19%	83.53%	-33.33%	142.86%	-712.50%	-133.33%	57.14%
Operating Cash Flow Growth	-28.52%	4.26%	-4.10%	-8.11%	87.42%	603.74%	-41.13%	351.41%	-54.68%	-163.04%	176.16%
Free Cash Flow Firm Growth	-13.09%	1.99%	1.35%	5.17%	79.36%	-172.28%	-155.20%	122.07%	-610.79%	-133.20%	79.87%
Invested Capital Growth	9.89%	33.31%	-10.91%	32.69%	-90.32%	723.89%	355.45%	7.60%	17.09%	23.03%	-24.16%
Revenue Q/Q Growth	18.16%	18.23%	-0.25%	11.83%	24.27%	9.75%	13.59%	6.34%	1.33%	-3.07%	10.05%
EBITDA Q/Q Growth	-1.21%	8.86%	-2.66%	10.03%	-127.76%	-4.87%	81.56%	-24.10%	-70.23%	-8.90%	28.24%
EBIT Q/Q Growth	-1.39%	8.34%	-2.80%	7.17%	-102.88%	-4.47%	43.86%	-29.21%	-48.72%	-8.00%	25.81%
NOPAT Q/Q Growth	-1.39%	8.34%	-2.80%	5.64%	18.52%	8.65%	67.49%	-22.27%	-48.96%	-8.00%	25.81%
Net Income Q/Q Growth	6.08%	8.09%	-3.38%	4.47%	10.96%	-4.36%	29.44%	-28.46%	-39.25%	-6.79%	24.26%
EPS Q/Q Growth	-102.10%	8.09%	-3.38%	12.63%	-2.82%	-5.00%	30.00%	-33.33%	-38.68%	-6.52%	23.44%
Operating Cash Flow Q/Q Growth	-1.17%	5.30%	-5.77%	2.85%	75.60%	14.51%	-14.57%	4.11%	-21.49%	-69.44%	285.01%
Free Cash Flow Firm Q/Q Growth	0.00%	2.65%	-5.06%	14.17%	31.90%	-33.15%	-4.65%	12.75%	-26.14%	-20.57%	64.33%
Invested Capital Q/Q Growth	-1.94%	15.63%	26.78%	-7.51%	21.65%	84.34%	37.96%	19.92%	10.84%	30.21%	-12.12%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	30.67%	36.49%	28.00%	40.98%	48.85%	53.60%	52.23%	53.53%	51.54%	49.18%	52.07%
EBITDA Margin	-143.01%	-87.90%	-85.90%	-49.43%	-56.04%	-6.15%	-1.16%	5.29%	-9.02%	-28.32%	-8.80%
Operating Margin	-152.17%	-94.72%	-92.64%	-58.50%	-24.27%	-4.62%	-1.60%	3.22%	-11.59%	-31.19%	-10.54%
EBIT Margin	-152.17%	-94.72%	-92.64%	-57.55%	-60.44%	-7.67%	-5.02%	3.03%	-11.57%	-31.19%	-10.54%
Profit (Net Income) Margin	-159.94%	-99.41%	-99.05%	-67.87%	-66.69%	-6.83%	-6.89%	2.21%	-11.81%	-29.77%	-10.21%
Tax Burden Percent	100.09%	100.01%	99.98%	100.01%	100.04%	100.61%	94.76%	97.89%	101.88%	101.07%	104.52%
Interest Burden Percent	105.01%	104.93%	106.93%	117.93%	110.29%	88.51%	144.87%	74.77%	100.16%	94.44%	92.68%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2.11%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-376.52%	-281.10%	-294.28%	-216.47%	-245.40%	-112.72%	-10.83%	25.33%	-65.97%	-137.75%	-60.36%
ROIC Less NNEP Spread (ROIC-NNEP)	-339.10%	-223.46%	-11.94%	-292.93%	-7.04%	-104.18%	1.74%	27.44%	-57.21%	-114.77%	-45.00%
Return on Net Nonoperating Assets (RNNOA)	283.02%	158.40%	4.23%	632.91%	5.28%	97.55%	-1.42%	-21.43%	44.30%	78.67%	27.06%
Return on Equity (ROE)	-93.50%	-122.70%	-290.04%	416.44%	-240.11%	-15.17%	-12.25%	3.89%	-21.67%	-59.08%	-33.30%
Cash Return on Invested Capital (CROIC)	-385.94%	-309.66%	-282.74%	-244.56%	-80.71%	-269.42%	-138.81%	18.00%	-81.71%	-158.41%	-32.88%
Operating Return on Assets (OROA)	-56.32%	-59.69%	-65.83%	-59.62%	-73.68%	-10.44%	-4.80%	2.62%	-9.47%	-23.26%	-10.32%
Return on Assets (ROA)	-59.20%	-62.65%	-70.38%	-70.31%	-81.30%	-9.30%	-6.60%	1.92%	-9.66%	-22.20%	-10.00%
Return on Common Equity (ROCE)	-93.50%	-122.70%	-290.04%	416.44%	-240.11%	-15.17%	-12.25%	3.89%	-21.67%	-59.08%	-33.30%
Return on Equity Simple (ROE_SIMPLE)	-145.72%	-114.10%	1,407.91%	250.56%	-93.40%	-12.70%	-9.39%	3.59%	-21.50%	-70.98%	-36.50%
Net Operating Profit after Tax (NOPAT)	-53	-48	-55	-44	-31	-12	-5.57	22	-65	-163	-69
NOPAT Margin	-106.52%	-66.30%	-64.85%	-40.95%	-16.99%	-3.23%	-1.12%	3.16%	-8.11%	-21.83%	-7.38%
Net Nonoperating Expense Percent (NNEP)	-37.41%	-57.64%	-282.34%	76.46%	-238.36%	-8.54%	-12.57%	-2.12%	-8.76%	-22.98%	-15.36%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-8.99%	-27.27%	-11.34%
Cost of Revenue to Revenue	69.33%	63.51%	72.00%	59.02%	51.15%	46.40%	47.77%	46.47%	48.46%	50.83%	47.93%
SG&A Expenses to Revenue	151.08%	107.92%	98.32%	80.28%	57.23%	45.74%	41.08%	37.21%	41.90%	47.14%	41.46%
R&D to Revenue	31.76%	23.28%	22.33%	19.20%	15.90%	12.48%	12.74%	13.10%	21.24%	33.22%	21.15%
Operating Expenses to Revenue	182.84%	131.21%	120.65%	99.48%	73.13%	58.22%	53.82%	50.31%	63.13%	80.37%	62.61%
Earnings before Interest and Taxes (EBIT)	-76	-69	-78	-62	-111	-28	-25	21	-93	-233	-99
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-71	-64	-72	-53	-103	-22	-5.79	37	-72	-212	-83
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.47	5.60	0.00	0.00	16.59	18.07	16.25	22.08	6.57	6.15	8.99
Price to Tangible Book Value (P/TBV)	5.73	5.79	0.00	0.00	16.59	18.07	16.25	22.08	6.57	6.15	8.99
Price to Revenue (P/Rev)	6.00	4.88	0.78	0.22	11.85	9.72	11.93	13.61	3.61	2.58	2.52
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	649.22	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.15%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	17.56	15.86	5.10	3.72	911.60	180.66	67.20	101.58	24.06	13.35	22.20
Enterprise Value to Revenue (EV/Rev)	5.20	4.27	1.06	0.80	11.15	9.24	11.36	13.12	3.19	2.34	2.34
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	247.84	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	433.56	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	415.80	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	79.85	229.80	82.80	50.66	0.00	90.89
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	585.04	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.54	0.46	-13.32	-2.63	0.00	0.00	0.55	0.65	0.64	0.91	1.33
Long-Term Debt to Equity	0.54	0.46	-13.32	-2.63	0.00	0.00	0.55	0.65	0.64	0.91	1.17
Financial Leverage	-0.83	-0.71	-0.35	-2.16	-0.75	-0.94	-0.82	-0.78	-0.77	-0.69	-0.60
Leverage Ratio	1.58	1.96	4.12	-5.92	2.95	1.63	1.86	2.03	2.24	2.66	3.33
Compound Leverage Factor	1.66	2.06	4.41	-6.98	3.26	1.44	2.69	1.52	2.25	2.51	3.09
Debt to Total Capital	35.04%	31.57%	108.12%	161.50%	0.00%	0.00%	35.66%	39.39%	39.16%	47.61%	57.01%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	6.65%
Long-Term Debt to Total Capital	35.04%	31.57%	108.12%	161.50%	0.00%	0.00%	35.66%	39.39%	39.16%	47.61%	50.37%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	64.96%	68.43%	-8.12%	-61.50%	100.00%	100.00%	64.34%	60.61%	60.84%	52.39%	42.99%
Debt to EBITDA	-0.41	-0.46	-1.09	-1.44	0.00	0.00	-35.04	7.57	-3.92	-1.35	-4.22
Net Debt to EBITDA	0.56	0.68	-0.32	-1.17	0.00	0.00	48.67	-9.20	4.62	0.86	1.98
Long-Term Debt to EBITDA	-0.41	-0.46	-1.09	-1.44	0.00	0.00	-35.04	7.57	-3.92	-1.35	-3.73
Debt to NOPAT	-0.56	-0.61	-1.45	-1.74	0.00	0.00	-36.44	12.69	-4.36	-1.75	-5.03
Net Debt to NOPAT	0.75	0.91	-0.43	-1.42	0.00	0.00	50.62	-15.44	5.13	1.12	2.36
Long-Term Debt to NOPAT	-0.56	-0.61	-1.45	-1.74	0.00	0.00	-36.44	12.69	-4.36	-1.75	-4.44
Altman Z-Score	-0.88	-0.59	-5.60	-7.56	13.17	14.92	10.38	12.93	3.11	1.09	1.72
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.02	4.03	2.93	1.78	2.83	2.78	6.14	6.15	5.14	3.83	2.93
Quick Ratio	4.14	3.21	2.06	0.97	2.48	2.24	5.46	5.57	4.43	2.94	2.24
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-54	-53	-52	-50	-10	-28	-71	16	-81	-188	-38
Operating Cash Flow to CapEx	-1,393.05%	-1,019.50%	-685.03%	-1,156.63%	-278.60%	214.45%	90.01%	785.32%	148.00%	-118.68%	125.97%
Free Cash Flow to Firm to Interest Expense	-13.92	-14.22	-9.20	-4.39	-0.80	0.00	-5.58	2.61	-12.97	-19.00	-4.35
Operating Cash Flow to Interest Expense	-15.73	-15.71	-10.72	-5.83	-0.65	0.00	1.93	18.44	8.13	-3.22	2.79
Operating Cash Flow Less CapEx to Interest Expense	-16.86	-17.25	-12.28	-6.34	-0.88	0.00	-0.21	16.09	2.64	-5.93	0.58
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.37	0.63	0.71	1.04	1.22	1.36	0.96	0.87	0.82	0.75	0.98
Accounts Receivable Turnover	7.68	6.71	6.68	6.73	6.57	8.86	7.75	7.29	7.11	6.79	8.54
Inventory Turnover	3.10	3.14	3.13	2.64	4.01	4.87	4.23	4.94	4.32	2.82	2.93
Fixed Asset Turnover	4.43	5.18	4.97	5.66	10.00	14.47	12.03	14.00	13.47	10.31	12.16
Accounts Payable Turnover	16.03	12.88	9.52	10.03	15.71	13.68	13.41	14.25	9.27	7.22	9.56
Days Sales Outstanding (DSO)	47.54	54.38	54.65	54.22	55.57	41.19	47.11	50.10	51.35	53.76	42.73
Days Inventory Outstanding (DIO)	117.75	116.18	116.55	138.48	90.99	74.88	86.38	73.92	84.46	129.21	124.55
Days Payable Outstanding (DPO)	22.77	28.33	38.35	36.39	23.24	26.67	27.22	25.61	39.37	50.58	38.20
Cash Conversion Cycle (CCC)	142.52	142.23	132.85	156.30	123.33	89.40	106.27	98.40	96.43	132.39	129.09
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	15	20	17	23	2.25	19	84	91	106	131	99
Invested Capital Turnover	3.53	4.24	4.54	5.29	14.44	34.89	9.70	8.03	8.13	6.31	8.18
Increase / (Decrease) in Invested Capital	1.33	4.91	-2.14	5.72	-21	16	66	6.42	16	24	-32
Enterprise Value (EV)	259	311	89	86	2,049	3,346	5,669	9,221	2,557	1,746	2,202
Market Capitalization	298	355	66	24	2,178	3,523	5,951	9,563	2,890	1,929	2,366
Book Value per Share	$2.32	$2.11	($0.19)	($2.88)	$2.29	$3.30	$5.89	$6.82	$6.84	$4.81	$4.01
Tangible Book Value per Share	$2.22	$2.04	($0.25)	($3.02)	$2.29	$3.30	$5.89	$6.82	$6.84	$4.81	$4.01
Total Capital	84	93	73	47	131	195	569	715	723	599	612
Total Debt	29	29	79	77	0.00	0.00	203	281	283	285	349
Total Long-Term Debt	29	29	79	77	0.00	0.00	203	281	283	285	308
Net Debt	-40	-44	23	62	-129	-176	-282	-342	-334	-183	-164
Capital Expenditures (CapEx)	4.41	5.76	8.93	5.72	2.99	20	27	14	34	27	19
Debt-free, Cash-free Net Working Capital (DFCFNWC)	3.38	7.36	5.08	14	-7.43	0.29	48	56	68	85	80
Debt-free Net Working Capital (DFNWC)	73	80	61	28	122	177	533	680	685	553	518
Net Working Capital (NWC)	73	80	61	28	122	177	533	680	685	553	477
Net Nonoperating Expense (NNE)	27	24	29	29	91	13	29	6.61	30	59	27
Net Nonoperating Obligations (NNO)	-40	-44	23	52	-129	-176	-282	-342	-334	-183	-164
Total Depreciation and Amortization (D&A)	4.56	4.97	5.68	8.73	8.08	5.51	19	16	20	22	16
Debt-free, Cash-free Net Working Capital to Revenue	6.79%	10.10%	6.03%	12.91%	-4.04%	0.08%	9.71%	7.95%	8.46%	11.34%	8.49%
Debt-free Net Working Capital to Revenue	146.13%	110.45%	71.95%	26.09%	66.13%	48.78%	106.93%	96.71%	85.46%	73.92%	55.11%
Net Working Capital to Revenue	146.13%	110.45%	71.95%	26.09%	66.13%	48.78%	106.93%	96.71%	85.46%	73.92%	50.78%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($34.20)	($25.00)	($27.30)	($12.87)	($2.55)	($0.42)	($0.56)	$0.25	($1.47)	($3.43)	($1.47)
Adjusted Weighted Average Basic Shares Outstanding	2.37M	3.03M	3.13M	44.70M	57.72M	59.73M	62.50M	63M	64.15M	64.97M	65.45M
Adjusted Diluted Earnings per Share	($34.20)	($25.00)	($27.30)	($12.87)	($2.55)	($0.42)	($0.56)	$0.24	($1.47)	($3.43)	($1.47)
Adjusted Weighted Average Diluted Shares Outstanding	2.37M	3.03M	3.13M	44.70M	57.72M	59.73M	62.50M	64.35M	64.15M	64.97M	65.45M
Adjusted Basic & Diluted Earnings per Share	($34.20)	($25.00)	($27.30)	($12.87)	($2.55)	($0.42)	($0.56)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	2.33M	2.89M	3.06M	5.68M	48.13M	58.51M	60.99M	63.87M	64.53M	65.63M	66.47M
Normalized Net Operating Profit after Tax (NOPAT)	-53	-48	-55	-44	-31	-12	-5.57	22	-65	-163	-69
Normalized NOPAT Margin	-106.52%	-66.30%	-64.85%	-40.95%	-16.99%	-3.23%	-1.12%	3.16%	-8.11%	-21.83%	-7.38%
Pre Tax Income Margin	-159.79%	-99.39%	-99.07%	-67.87%	-66.66%	-6.79%	-7.27%	2.26%	-11.59%	-29.46%	-9.77%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-19.40	-18.45	-13.68	-5.46	-8.63	0.00	-1.96	3.52	-14.93	-23.60	-11.42
NOPAT to Interest Expense	-13.58	-12.91	-9.57	-3.89	-2.43	0.00	-0.44	3.67	-10.47	-16.52	-7.99
EBIT Less CapEx to Interest Expense	-20.53	-19.99	-15.24	-5.96	-8.86	0.00	-4.10	1.17	-20.42	-26.31	-13.63
NOPAT Less CapEx to Interest Expense	-14.71	-14.45	-11.14	-4.39	-2.66	0.00	-2.58	1.32	-15.96	-19.23	-10.21
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-31.24%

This table displays calculated financial ratios and metrics derived from Tandem Diabetes Care's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	13.87%	5.00%	-3.71%	-2.17%	-9.25%	-10.75%	13.16%	13.27%	31.43%	43.62%	22.30%
EBITDA Growth	-468.10%	-174.99%	-1,054.12%	-366.23%	39.39%	-134.81%	69.73%	21.92%	12.11%	108.10%	-213.24%
EBIT Growth	-748.10%	-239.92%	-733.34%	-217.08%	33.58%	-97.21%	67.39%	20.70%	17.28%	98.34%	-190.03%
NOPAT Growth	-534.65%	-200.74%	-733.34%	-217.08%	33.58%	-97.21%	67.39%	20.70%	17.28%	-11.90%	-190.03%
Net Income Growth	-945.18%	-246.68%	-741.81%	-137.61%	32.69%	-89.25%	65.52%	13.87%	29.46%	102.52%	-205.64%
EPS Growth	-944.44%	-241.18%	-734.78%	-129.17%	32.89%	-87.50%	66.15%	14.55%	31.37%	0.00%	-203.08%
Operating Cash Flow Growth	-29.88%	-70.36%	-232.80%	-191.62%	-99.77%	-223.99%	56.37%	16.57%	48,589.09%	248.52%	-128.59%
Free Cash Flow Firm Growth	-674.15%	-570.79%	-648.36%	-54.24%	50.18%	-75.35%	54.73%	-22.17%	-15.25%	108.43%	45.06%
Invested Capital Growth	26.67%	17.09%	22.59%	9.85%	4.74%	23.03%	19.36%	21.93%	12.36%	-24.16%	-46.96%
Revenue Q/Q Growth	2.14%	7.80%	-23.18%	15.67%	-5.25%	6.02%	-2.60%	15.77%	9.94%	15.85%	-17.06%
EBITDA Q/Q Growth	-499.40%	69.38%	-863.41%	73.63%	22.08%	-18.62%	-24.21%	31.99%	12.28%	110.93%	-4,905.66%
EBIT Q/Q Growth	-288.05%	62.57%	-618.96%	69.64%	18.72%	-11.14%	-18.88%	26.16%	15.21%	97.77%	-20,669.42%
NOPAT Q/Q Growth	-288.05%	62.57%	-618.96%	69.64%	18.72%	-11.14%	-18.88%	26.16%	15.21%	-50.36%	-208.10%
Net Income Q/Q Growth	-225.25%	67.63%	-681.39%	71.12%	7.87%	8.98%	-42.37%	27.86%	24.54%	103.25%	-17,392.19%
EPS Q/Q Growth	-216.67%	68.42%	-700.00%	71.35%	7.27%	11.76%	-44.44%	27.69%	25.53%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	246.95%	-75.69%	-414.88%	65.50%	100.87%	-13,220.00%	-10.81%	34.03%	607.66%	-59.98%	-270.55%
Free Cash Flow Firm Q/Q Growth	-124.67%	47.68%	-287.84%	66.17%	27.43%	-84.13%	-0.13%	8.69%	31.54%	113.47%	-752.65%
Invested Capital Q/Q Growth	-0.74%	10.84%	-3.23%	3.18%	-5.37%	30.21%	-6.12%	5.41%	-12.79%	-12.12%	-34.35%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	51.05%	52.39%	48.95%	51.93%	48.35%	47.41%	49.39%	50.83%	51.09%	55.71%	50.51%
EBITDA Margin	-20.49%	-5.82%	-72.97%	-16.64%	-13.68%	-15.31%	-19.52%	-11.47%	-9.15%	0.86%	-50.00%
Operating Margin	-23.22%	-8.06%	-75.46%	-19.81%	-16.99%	-17.82%	-21.74%	-13.87%	-10.70%	-0.21%	-51.56%
EBIT Margin	-23.22%	-8.06%	-75.46%	-19.81%	-16.99%	-17.82%	-21.74%	-13.87%	-10.70%	-0.21%	-51.56%
Profit (Net Income) Margin	-23.94%	-7.19%	-73.13%	-18.26%	-17.76%	-15.25%	-22.29%	-13.89%	-9.53%	0.27%	-55.69%
Tax Burden Percent	103.42%	98.38%	100.23%	103.31%	107.26%	95.82%	108.06%	103.60%	102.82%	4,718.75%	106.94%
Interest Burden Percent	99.70%	90.64%	96.69%	89.23%	97.41%	89.30%	94.84%	96.65%	86.67%	-2.75%	101.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-4,618.75%	0.00%
Return on Invested Capital (ROIC)	-149.81%	-45.90%	-449.58%	-108.12%	-93.50%	-78.68%	-103.91%	-65.62%	-59.98%	-79.47%	-377.74%
ROIC Less NNEP Spread (ROIC-NNEP)	-144.89%	-44.89%	-437.91%	-105.13%	-89.46%	-76.56%	-96.30%	-59.96%	-57.04%	-95.74%	-334.09%
Return on Net Nonoperating Assets (RNNOA)	114.26%	34.76%	332.55%	77.77%	65.60%	52.48%	58.96%	34.88%	34.99%	57.57%	176.54%
Return on Equity (ROE)	-35.55%	-11.14%	-117.04%	-30.35%	-27.90%	-26.20%	-44.94%	-30.74%	-24.99%	-21.89%	-201.20%
Cash Return on Invested Capital (CROIC)	-74.39%	-81.71%	-174.23%	-169.54%	-158.64%	-158.41%	-108.93%	-102.43%	-99.35%	-32.88%	-71.52%
Operating Return on Assets (OROA)	-19.35%	-6.60%	-60.90%	-15.79%	-13.19%	-13.28%	-17.67%	-11.72%	-9.63%	-0.20%	-54.41%
Return on Assets (ROA)	-19.95%	-5.88%	-59.02%	-14.55%	-13.78%	-11.37%	-18.11%	-11.73%	-8.58%	0.26%	-58.76%
Return on Common Equity (ROCE)	-35.55%	-11.14%	-117.04%	-30.35%	-27.90%	-26.20%	-44.94%	-30.74%	-24.99%	-21.89%	-201.20%
Return on Equity Simple (ROE_SIMPLE)	-16.10%	0.00%	-60.15%	-68.18%	-66.39%	0.00%	-58.20%	-58.36%	-53.33%	0.00%	-118.40%
Net Operating Profit after Tax (NOPAT)	-33	-12	-89	-27	-22	-25	-29	-22	-18	-27	-85
NOPAT Margin	-16.25%	-5.64%	-52.82%	-13.87%	-11.90%	-12.47%	-15.22%	-9.71%	-7.49%	-9.72%	-36.10%
Net Nonoperating Expense Percent (NNEP)	-4.91%	-1.01%	-11.67%	-2.99%	-4.03%	-2.11%	-7.60%	-5.66%	-2.95%	16.27%	-43.65%
Return On Investment Capital (ROIC_SIMPLE)	-	-1.72%	-	-	-	-4.10%	-	-	-	-4.49%	-16.76%
Cost of Revenue to Revenue	48.95%	47.61%	51.05%	48.07%	51.65%	52.59%	50.61%	49.17%	48.91%	44.29%	49.49%
SG&A Expenses to Revenue	41.12%	44.30%	53.02%	49.82%	42.74%	43.57%	47.01%	42.47%	40.84%	37.44%	48.57%
R&D to Revenue	33.15%	16.15%	71.38%	21.91%	22.61%	21.65%	24.13%	22.23%	20.95%	18.47%	53.51%
Operating Expenses to Revenue	74.27%	60.45%	124.41%	71.74%	65.35%	65.22%	71.14%	64.70%	61.79%	55.91%	102.07%
Earnings before Interest and Taxes (EBIT)	-47	-18	-128	-39	-32	-35	-42	-31	-26	-0.58	-121
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-42	-13	-124	-33	-25	-30	-37	-25	-22	2.44	-117
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	7.29	6.57	7.74	4.82	4.30	6.15	9.50	11.13	11.68	8.99	8.20
Price to Tangible Book Value (P/TBV)	7.29	6.57	7.74	4.82	4.30	6.15	9.50	11.13	11.68	8.99	8.20
Price to Revenue (P/Rev)	3.89	3.61	3.30	2.01	1.75	2.58	3.00	3.27	3.25	2.52	1.30
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	28.65	24.06	23.19	12.84	11.33	13.35	17.83	19.30	23.50	22.20	18.18
Enterprise Value to Revenue (EV/Rev)	3.47	3.19	3.00	1.72	1.48	2.34	2.84	3.14	3.10	2.34	1.20
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	42.74	50.66	130.03	266.47	0.00	0.00	0.00	0.00	421.41	90.89	84.88
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.67	0.64	0.84	0.86	0.91	0.91	1.43	1.49	1.47	1.33	2.25
Long-Term Debt to Equity	0.67	0.64	0.84	0.86	0.91	0.91	1.43	1.31	1.30	1.17	1.99
Financial Leverage	-0.79	-0.77	-0.76	-0.74	-0.73	-0.69	-0.61	-0.58	-0.61	-0.60	-0.53
Leverage Ratio	2.34	2.24	2.54	2.55	2.70	2.66	3.26	3.35	3.44	3.33	4.68
Compound Leverage Factor	2.33	2.03	2.45	2.27	2.63	2.38	3.09	3.23	2.98	-0.09	4.72
Debt to Total Capital	40.13%	39.16%	45.58%	46.32%	47.54%	47.61%	58.84%	59.80%	59.45%	57.01%	69.23%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	6.97%	6.93%	6.65%	8.07%
Long-Term Debt to Total Capital	40.13%	39.16%	45.58%	46.32%	47.54%	47.61%	58.84%	52.83%	52.52%	50.37%	61.16%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	59.87%	60.84%	54.42%	53.68%	52.46%	52.39%	41.16%	40.20%	40.55%	42.99%	30.77%
Debt to EBITDA	-6.66	-3.92	-1.53	-1.35	-1.46	-1.35	-2.77	-2.94	-3.02	-4.22	-2.15
Net Debt to EBITDA	7.68	4.62	1.27	1.06	1.10	0.86	0.96	0.88	1.08	1.98	0.55
Long-Term Debt to EBITDA	-6.66	-3.92	-1.53	-1.35	-1.46	-1.35	-2.77	-2.60	-2.67	-3.73	-1.90
Debt to NOPAT	-6.48	-4.36	-1.97	-1.75	-1.88	-1.75	-3.37	-3.57	-3.73	-5.03	-2.80
Net Debt to NOPAT	7.47	5.13	1.64	1.37	1.41	1.12	1.17	1.07	1.34	2.36	0.72
Long-Term Debt to NOPAT	-6.48	-4.36	-1.97	-1.75	-1.88	-1.75	-3.37	-3.16	-3.29	-4.44	-2.47
Altman Z-Score	3.36	3.35	2.43	1.67	1.36	1.77	1.87	2.06	2.20	2.06	0.33
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.81	5.14	4.43	4.38	4.05	3.83	3.81	3.05	2.90	2.93	2.30
Quick Ratio	4.16	4.43	3.57	3.47	3.20	2.94	2.91	2.29	2.24	2.24	1.72
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-53	-28	-108	-37	-27	-49	-49	-45	-31	4.13	-27
Operating Cash Flow to CapEx	174.64%	103.43%	-207.59%	-85.71%	1.02%	-138.80%	-179.40%	-81.58%	511.15%	349.20%	-616.46%
Free Cash Flow to Firm to Interest Expense	-33.90	-17.70	-66.35	-22.86	-5.50	-27.19	-15.51	-25.00	-16.45	2.22	-14.48
Operating Cash Flow to Interest Expense	15.19	3.69	-11.22	-3.94	0.01	-4.00	-2.53	-2.94	14.36	5.76	-9.82
Operating Cash Flow Less CapEx to Interest Expense	6.49	0.12	-16.62	-8.54	-1.10	-6.89	-3.93	-6.55	11.55	4.11	-11.41
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.83	0.82	0.81	0.80	0.78	0.75	0.81	0.84	0.90	0.98	1.06
Accounts Receivable Turnover	7.90	7.11	8.57	7.81	7.24	6.79	8.35	8.09	8.23	8.54	8.96
Inventory Turnover	4.45	4.32	3.69	3.27	3.07	2.82	2.74	2.62	2.90	2.93	3.18
Fixed Asset Turnover	12.91	13.47	12.76	11.92	10.38	10.31	10.12	10.45	10.90	12.16	12.54
Accounts Payable Turnover	8.58	9.27	7.75	7.16	7.09	7.22	7.56	7.73	9.04	9.56	8.70
Days Sales Outstanding (DSO)	46.22	51.35	42.61	46.75	50.42	53.76	43.69	45.13	44.33	42.73	40.76
Days Inventory Outstanding (DIO)	81.99	84.46	99.02	111.51	118.76	129.21	133.39	139.19	125.91	124.55	114.66
Days Payable Outstanding (DPO)	42.56	39.37	47.08	50.97	51.51	50.58	48.31	47.19	40.38	38.20	41.95
Cash Conversion Cycle (CCC)	85.66	96.43	94.55	107.29	117.67	132.39	128.78	137.12	129.86	129.09	113.47
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	96	106	103	106	100	131	123	129	113	99	65
Invested Capital Turnover	9.22	8.13	8.51	7.80	7.86	6.31	6.83	6.76	8.01	8.18	10.47
Increase / (Decrease) in Invested Capital	20	16	19	9.52	4.54	24	20	23	12	-32	-58
Enterprise Value (EV)	2,747	2,557	2,385	1,363	1,138	1,746	2,189	2,498	2,651	2,202	1,183
Market Capitalization	3,073	2,890	2,620	1,586	1,352	1,929	2,309	2,602	2,776	2,366	1,274
Book Value per Share	$6.57	$6.84	$5.25	$5.09	$4.83	$4.81	$3.72	$3.62	$3.63	$4.01	$2.34
Tangible Book Value per Share	$6.57	$6.84	$5.25	$5.09	$4.83	$4.81	$3.72	$3.62	$3.63	$4.01	$2.34
Total Capital	705	723	622	613	599	599	591	582	586	612	505
Total Debt	283	283	284	284	285	285	347	348	348	349	349
Total Long-Term Debt	283	283	284	284	285	285	347	307	308	308	309
Net Debt	-326	-334	-236	-223	-214	-183	-120	-104	-125	-164	-90
Capital Expenditures (CapEx)	14	5.63	8.83	7.38	5.40	5.20	4.46	6.47	5.24	3.07	2.97
Debt-free, Cash-free Net Working Capital (DFCFNWC)	52	68	67	82	73	85	74	81	61	80	47
Debt-free Net Working Capital (DFNWC)	661	685	587	590	571	553	542	533	534	518	416
Net Working Capital (NWC)	661	685	587	590	571	553	542	493	494	477	375
Net Nonoperating Expense (NNE)	16	3.41	34	8.61	11	5.46	14	9.27	4.99	-28	46
Net Nonoperating Obligations (NNO)	-326	-334	-236	-223	-214	-183	-120	-104	-125	-164	-90
Total Depreciation and Amortization (D&A)	5.59	4.95	4.21	6.21	6.15	4.93	4.26	5.33	3.77	3.02	3.67
Debt-free, Cash-free Net Working Capital to Revenue	6.57%	8.46%	8.45%	10.43%	9.45%	11.34%	9.66%	10.16%	7.12%	8.49%	4.82%
Debt-free Net Working Capital to Revenue	83.55%	85.46%	73.84%	74.61%	74.02%	73.92%	70.42%	67.00%	62.52%	55.11%	42.32%
Net Working Capital to Revenue	83.55%	85.46%	73.84%	74.61%	74.02%	73.92%	70.42%	61.91%	57.77%	50.78%	38.18%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.76)	($0.25)	($1.92)	($0.55)	($0.51)	($0.45)	($0.65)	($0.47)	($0.35)	$0.00	($1.97)
Adjusted Weighted Average Basic Shares Outstanding	64.24M	64.15M	64.55M	64.83M	65.12M	64.97M	65.33M	64.99M	65.54M	65.45M	66.40M
Adjusted Diluted Earnings per Share	($0.76)	($0.24)	($1.92)	($0.55)	($0.51)	($0.45)	($0.65)	($0.47)	($0.35)	$0.00	($1.97)
Adjusted Weighted Average Diluted Shares Outstanding	64.24M	64.15M	64.55M	64.83M	65.12M	64.97M	65.33M	64.99M	65.54M	65.45M	66.40M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	64.30M	64.53M	64.62M	65.08M	65.21M	65.63M	64.59M	65.46M	65.68M	66.47M	66.61M
Normalized Net Operating Profit after Tax (NOPAT)	-33	-12	-89	-27	-22	-25	-29	-22	-18	-0.41	-85
Normalized NOPAT Margin	-16.25%	-5.64%	-52.82%	-13.87%	-11.90%	-12.47%	-15.22%	-9.71%	-7.49%	-0.14%	-36.10%
Pre Tax Income Margin	-23.15%	-7.31%	-72.96%	-17.68%	-16.55%	-15.91%	-20.62%	-13.40%	-9.27%	0.01%	-52.08%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-30.14	-11.26	-78.22	-24.18	-6.52	-19.45	-13.17	-17.16	-13.99	-0.31	-64.92
NOPAT to Interest Expense	-21.09	-7.88	-54.76	-16.93	-4.56	-13.61	-9.22	-12.01	-9.79	-14.77	-45.44
EBIT Less CapEx to Interest Expense	-38.83	-14.82	-83.63	-28.78	-7.63	-22.33	-14.58	-20.77	-16.80	-1.96	-66.51
NOPAT Less CapEx to Interest Expense	-29.79	-11.45	-60.16	-21.52	-5.68	-16.50	-10.63	-15.62	-12.60	-16.42	-47.04
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-31.24%	0.00%

Frequently Asked Questions About Tandem Diabetes Care's Financials

When does Tandem Diabetes Care's fiscal year end?

According to the most recent income statement we have on file, Tandem Diabetes Care's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Tandem Diabetes Care's net income changed over the last 10 years?

Tandem Diabetes Care's net income appears to be on an upward trend, with a most recent value of -$96.03 million in 2024, rising from -$79.52 million in 2014. The previous period was -$222.61 million in 2023. See Tandem Diabetes Care's forecast for analyst expectations on what’s next for the company.

What is Tandem Diabetes Care's operating income?

Tandem Diabetes Care's total operating income in 2024 was -$99.13 million, based on the following breakdown:

Total Gross Profit: $489.57 million
Total Operating Expenses: $588.70 million

How has Tandem Diabetes Care revenue changed over the last 10 years?

Over the last 10 years, Tandem Diabetes Care's total revenue changed from $49.72 million in 2014 to $940.20 million in 2024, a change of 1,790.9%.

How much debt does Tandem Diabetes Care have?

Tandem Diabetes Care's total liabilities were at $704.56 million at the end of 2024, a 10.3% increase from 2023, and a 1,257.7% increase since 2014.

How much cash does Tandem Diabetes Care have?

In the past 10 years, Tandem Diabetes Care's cash and equivalents has ranged from $13.70 million in 2017 to $172.52 million in 2022, and is currently $69.23 million as of their latest financial filing in 2024.

How has Tandem Diabetes Care's book value per share changed over the last 10 years?

Over the last 10 years, Tandem Diabetes Care's book value per share changed from 2.32 in 2014 to 4.01 in 2024, a change of 72.5%.

Related Companies

This page (NASDAQ:TNDM) was last updated on 5/7/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tandem Diabetes Care (TNDM) Financials

Frequently Asked Questions About Tandem Diabetes Care's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tandem Diabetes Care (TNDM) Financials

Annual Income Statements for Tandem Diabetes Care

Quarterly Income Statements for Tandem Diabetes Care

Annual Cash Flow Statements for Tandem Diabetes Care

Quarterly Cash Flow Statements for Tandem Diabetes Care

Annual Balance Sheets for Tandem Diabetes Care

Quarterly Balance Sheets for Tandem Diabetes Care

Annual Metrics and Ratios for Tandem Diabetes Care

Quarterly Metrics and Ratios for Tandem Diabetes Care

Frequently Asked Questions About Tandem Diabetes Care's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools